- Home
- PBH
as 12-20-2024 3:40pm EST
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 4.1B | IPO Year: | 2005 |
| Target Price: | $83.67 | AVG Volume (30 days): | 279.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $57.95 - $86.36 | Next Earning Date: | 02-06-2025 |
| Revenue: | $1,110,659,000 | Revenue Growth: | -1.45% |
| Revenue Growth (this year): | 1.66% | Revenue Growth (next year): | 2.27% |
Stock Insider Trading Activity of Prestige Consumer Healthcare Inc. (PBH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lombardi Ronald M. | PBH | Chief Executive Officer | Nov 19 '24 | Sell | $82.60 | 10,875 | $898,240.83 | 320,952 | |
| Lombardi Ronald M. | PBH | Chief Executive Officer | Nov 18 '24 | Sell | $82.54 | 82,237 | $6,789,764.29 | 320,952 | |
| Fritz Mary Beth | PBH | SVP Quality & Regulatory | Nov 12 '24 | Sell | $81.96 | 9,885 | $810,266.31 | 18,835 | |
| Sacco Christine | PBH | Chief Financial Officer | Nov 12 '24 | Sell | $82.01 | 24,686 | $2,024,498.86 | 30,123 | |
| P'Pool William | PBH | See Remarks | Nov 12 '24 | Sell | $81.85 | 8,987 | $735,585.95 | 20,058 | |
| Mekhail Adel | PBH | EVP, Marketing & Sales | Nov 12 '24 | Sell | $82.00 | 9,063 | $743,166.00 | 18,365 |
Latest Prestige Consumer Healthcare Inc. News
PBH Breaking Stock News: Dive into PBH Ticker-Specific Updates for Smart Investing
Argus Research
5 days ago
PBH: Lowering target price to $84.00
Argus Research
12 days ago
PBH: Lowering target price to $88.00
Simply Wall St.
13 days ago
Has Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Argus Research
19 days ago
PBH: Raising target price to $89.00
Argus Research
a month ago
PBH: What does Argus have to say about PBH?
Argus Research
a month ago
PBH: Raising target price to $86.00
Zacks
a month ago
All You Need to Know About Prestige Consumer Healthcare (PBH) Rating Upgrade to Buy
Simply Wall St.
a month ago
Prestige Consumer Healthcare Inc. (NYSE:PBH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$85.29
Compare PBH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PBH Prestige Consumer Healthcare Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.